Ceribell, Inc. (CBLL) AI Stock Analysis

• Market Cap: $800.90M
• Dividend Yield: N/A
• Average Volume (3M): 525.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.37
• Shares Outstanding: 37,095,690
• 10 Day Avg. Volume: 700,930
• 30 Day Avg. Volume: 525,444
• PEG Ratio: 1.93
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 12.34
• P/FCF Ratio: -22.20
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 3.33
• Enterprise Value/Gross Profit: 3.78
• Enterprise Value/Ebitda: -5.61
• 1Y Price Target: $25.17
• Price Target Upside: 14.46% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -1.51
• Revenue Forecast (FY): $88.18M

• Rating: 61 Neutral
• Price Target: $21.50 ▼(-2.23% Downside)

Ceribell, Inc. benefits from strong technical momentum and positive corporate events, but faces challenges with profitability and valuation. The company's growth potential is promising, but operational inefficiencies and financial risks temper the overall outlook.

Positive Factors

FDA Clearance for Delirium Device

This FDA clearance enhances Ceribell's product portfolio, addressing a significant unmet need and potentially improving patient outcomes, strengthening its competitive position in the healthcare technology market.

Revenue Growth

Strong revenue growth indicates robust demand for Ceribell's products, supporting long-term business expansion and market penetration efforts, particularly in the healthcare sector.

Supply Chain Expansion

Expanding the supply chain enhances operational resilience and market positioning, reducing dependency on single sources and potentially lowering production costs.

Negative Factors

Operating Expenses Increase

Rising operating expenses could pressure profitability and cash flow, challenging Ceribell's ability to maintain financial health and invest in growth initiatives.

Net Loss Widened

An increasing net loss indicates ongoing financial challenges, which may hinder Ceribell's ability to achieve sustainable profitability and necessitate further external funding.

Cash Flow Management Issues

Negative cash flow highlights potential liquidity constraints, impacting Ceribell's capacity to fund operations and strategic initiatives without external financing.

Ceribell, Inc. Business Overview & Revenue Model

Company Description

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.

How the Company Makes Money

Ceribell generates revenue primarily through the sale of its EEG monitoring devices and associated services. The company has established partnerships with hospitals and healthcare systems that utilize its technology in their neurology departments. Additionally, Ceribell may offer subscription-based services for data management and analysis, enhancing patient monitoring capabilities over time. Revenue is also driven by ongoing support, maintenance services, and potential future collaborations with pharmaceutical companies focused on epilepsy treatments. Furthermore, reimbursement from insurance providers for the use of their devices plays a significant role in the company's financial model.

Ceribell, Inc. Financial Statement Overview

Summary

Ceribell, Inc. is experiencing strong revenue growth and has improved its equity position significantly. However, the company is still operating at a loss, with negative cash flow and high operating expenses, indicating ongoing financial challenges.

Income Statement

Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.

Balance Sheet

The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.

Cash Flow

Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	82.81M	65.44M	45.23M	25.92M
Gross Profit	72.87M	56.75M	38.16M	21.49M
EBITDA	-49.12M	-37.32M	-26.51M	-35.06M
Net Income	-52.46M	-40.45M	-29.46M	-37.16M
Balance Sheet
Total Assets	199.53M	225.41M	58.92M	86.46M
Cash, Cash Equivalents and Short-Term Investments	168.54M	194.37M	34.49M	68.23M
Total Debt	21.34M	21.96M	14.20M	18.22M
Total Liabilities	35.44M	34.25M	171.17M	172.86M
Stockholders Equity	164.08M	191.16M	-112.25M	-86.40M
Cash Flow
Free Cash Flow	-41.23M	-36.38M	-30.14M	-32.52M
Operating Cash Flow	-40.16M	-35.04M	-29.16M	-32.00M
Investing Cash Flow	-144.74M	-1.60M	-1.76M	-1.40M
Financing Cash Flow	194.53M	196.52M	-2.82M	49.80M

Ceribell, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBLL, the sentiment is Positive. The current price of 21.99 is above the 20-day moving average (MA) of 18.82, above the 50-day MA of 14.99, and above the 200-day MA of 15.58, indicating a bullish trend. The MACD of 2.10 indicates Negative momentum. The RSI at 73.68 is Negative, neither overbought nor oversold. The STOCH value of 51.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBLL.

Ceribell, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DCTH	64 Neutral	$351.72M	1,154.65	1.94%	―	251.54%	―
CBLL	61 Neutral	$800.90M	-14.74	-59.78%	―	―	―
BFLY	59 Neutral	$800.75M	-10.31	-41.42%	―	16.04%	28.91%
CTKB	58 Neutral	$615.03M	-47.48	-3.36%	―	-2.18%	-30.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VREX	50 Neutral	$496.65M	-7.14	-13.95%	―	4.14%	-45.29%
SRDX	43 Neutral	―	―	-15.36%	―	-0.02%	-1196.44%

Ceribell, Inc. Corporate Events

Ceribell, Inc. Extends Sunnyvale Office Leases

On December 11, 2025, Ceribell, Inc. announced amendments to two of its office space leases in Sunnyvale, California. The company extended the lease at 625 N. Pastoria Ave. to January 31, 2028, with a monthly rent of $34,821, and the lease at 360 N. Pastoria Ave. to the same date, with a monthly rent of $74,147. These lease extensions indicate Ceribell’s continued commitment to maintaining its operational presence in Sunnyvale, which could provide stability and predictability for its stakeholders.

Ceribell, Inc. Gains FDA Clearance for Delirium Device

On December 9, 2025, Ceribell, Inc. announced that the U.S. Food and Drug Administration granted 510(k) clearance for its proprietary delirium monitoring solution, marking it as the first FDA-cleared device for delirium screening and monitoring. This clearance enhances the Ceribell System’s capabilities as an AI-powered brain monitoring platform, addressing a significant unmet need in delirium monitoring and potentially improving patient outcomes by providing continuous, reliable evaluation. The solution’s validation through rigorous studies underscores its reliability, and the clearance follows a Breakthrough Device Designation received in 2022, highlighting its innovative impact on the healthcare industry.

Ceribell Gains FDA Clearance for Seizure Detection Algorithm

On November 24, 2025, Ceribell, Inc. announced that the FDA granted 510(k) clearance for its ClarityⓇ algorithm, making it the first FDA-cleared seizure detection algorithm for pre-term neonates through adults. This clearance addresses a critical gap in neonatal care by enabling rapid bedside detection and treatment of non-convulsive seizures, potentially improving outcomes for high-risk newborns. The clearance was supported by data from over 700 patients, marking the largest validation dataset for neonatal seizure detection, and highlights the importance of timely intervention in neonatal care.

Ceribell Expands Supply Chain with New Amendment

Ceribell, Inc. has been working with Shenzhen Everwin Precision Technology Co., Ltd. under a Corporate Supply Agreement initially established in January 2022. This agreement involves the supply of small and large headbands and grants Ceribell broad license rights to necessary product materials. The agreement has undergone several amendments, with the latest Amendment No. 3, dated September 22, 2025, designating Everwin Vietnam as an agent and providing for deliveries from Vietnam. These amendments extend the agreement’s term and expand the company’s operational capabilities, potentially enhancing its market positioning by diversifying its supply chain and production locations.

Ceribell Appoints Erica Rogers to Board of Directors

On September 17, 2025, Ceribell, Inc. appointed Erica Rogers to its Board of Directors, highlighting her extensive experience in leading high-growth medical device companies. Rogers’ appointment is seen as a strategic move to support Ceribell’s mission to expand nationwide access to its point-of-care EEG system, which has already improved care for critically ill patients in over 550 hospitals. Her leadership is expected to be instrumental in establishing the Ceribell System as the standard of care in acute settings.